Sandimmun neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis.
Girault
D
D
Sandoz Laboratories Rueil Malmaison, France.
Haloun
A
A
Viard
L
L
Bellon
G
G
Gottrand
F
F
Guillemain
R
R
Lenoir
G
G
Ladurie
F L
FL
Plouvier
E
E
Storni
V
V
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D001682:Biological Availability; D002648:Child; D016572:Cyclosporine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D003550:Cystic Fibrosis / Q000378:metabolism / Q000601:surgery*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D016041:Heart-Lung Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D016031:Liver Transplantation / Q000276:immunology*; D016040:Lung Transplantation / Q000276:immunology*; D008297:Male; D008657:Metabolic Clearance Rate; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors
D007166:Immunosuppressive Agents; D013256:Steroids; D016572:Cyclosporine; D001379:Azathioprine